BioIVT Launches LEUKOMAX XL for Enhanced Cellular Research
BioIVT, a leading provider of biospecimen solutions, has launched a groundbreaking product called LEUKOMAX XL. This innovative leukopak solution offers researchers an exceptional advantage by providing a minimum of 15 billion total nucleated cells (TNC) from a single donor collection. With a significant enhancement in cell yield, this solution contains more than 50% additional cells compared to standard leukopak products.
Why LEUKOMAX XL is a Game Changer
Researchers in the field of cell and gene therapies will benefit immensely from the introduction of LEUKOMAX XL. According to Dr. Parijat Jain, Vice President, CGT at BioIVT, the larger cell count from this product significantly minimizes delays and cuts down on costs. Researchers can now acquire more cells conveniently, without the need for multiple purchases of leukopaks, streamlining their research processes.
Addressing Market Demand for Advanced Therapeutics
In light of the increasing prevalence of blood disorders and autoimmune diseases, the demand for high-quality cellular starting materials continues to rise. BioIVT’s LEUKOMAX XL meets the industry needs with its high yield and efficient donor collection methods. This offering aligns well with the industry's shift towards personalized medicine and advanced research methodologies.
Unmatched Experience in Biospecimen Procurement
BioIVT brings over 35 years of expertise in biospecimen procurement to the table. The company boasts a diverse donor pool that includes over 600 recallable, consented donors located in both the U.S. and the U.K. Ensuring quality and compliance, all products collected are done under strict Institutional Review Board (IRB) protocols adhering to FDA and Human Tissue Authority (HTA) guidelines.
About BioIVT
As a trusted partner in ELEVATING SCIENCE®, BioIVT leverages its specialized knowledge in delivering high-quality biospecimen solutions and research services. They cater to various fields such as control and disease state samples, animal tissues, and cell and gene therapy products. By providing access to clinical specimens coupled with comprehensive clinical data, the company supports precision medicine initiatives aimed at enhancing patient outcomes.
How to Engage with BioIVT
For further information about BioIVT and their offerings, you can explore their website at www.bioivt.com. Stay connected with BioIVT by following them on professional networks like LinkedIn to keep up with their latest advancements and services.
Frequently Asked Questions
What is LEUKOMAX XL?
LEUKOMAX XL is a new leukopak product from BioIVT that delivers a minimum of 15 billion total nucleated cells from a single donor collection, surpassing standard leukopaks significantly in yield.
Why should researchers choose LEUKOMAX XL?
This product allows researchers to obtain a larger number of cells without purchasing additional leukopaks, thus saving time and reducing costs associated with research and development.
What is the main benefit of using LEUKOMAX XL?
With its high cell yield and streamlined procurement process, LEUKOMAX XL enables researchers to accelerate their projects significantly, facilitating advancements in cell and gene therapies.
How does BioIVT ensure quality in their biospecimens?
BioIVT adheres to strict IRB protocols and guidelines from the FDA and HTA, ensuring that all products are collected and processed to maintain high-quality standards.
How can I learn more about BioIVT's services?
To learn more, visit BioIVT's official website or follow their LinkedIn page, where they regularly update their service offerings and company news.
